New York, Feb 15, 2026, 11:43 (EST) — The market wrapped up for the day.
- Eli Lilly shares traded at $1,040.00, up roughly 0.2% from the previous close.
- A filing showed a $1.5 billion pre-launch inventory build tied to the oral obesity candidate orforglipron.
- Presidents Day has U.S. stock markets closed on Monday, so trading resumes with the cash session Tuesday.
Eli Lilly and Company shares will be in the spotlight again when U.S. markets open Tuesday. The company revealed a $1.5 billion pre-launch inventory buildup for its oral weight-loss candidate, orforglipron. The stock last changed hands at $1,040.00, up roughly 0.2% from the previous finish. With markets closed Monday for Presidents Day, investors get one more day to process the update.
Inventory is crucial here: pills might push the market well past the current limits set by weekly injections, but supply has kept hitting a wall during the GLP-1 surge. These drugs work by imitating gut hormones that suppress appetite and regulate blood sugar—fueling obesity and diabetes therapies into one of the fastest-growing arenas out there.
Lilly’s valuation now hinges on its ability to keep products flowing and coverage steady for patients. In this scenario, a hint about manufacturing can swing the shares as sharply as any trial result—particularly with the next big trigger in the hands of regulators, not Lilly itself.
Lilly disclosed in a securities filing this week that its “pre-launch inventories” totaled $1.5 billion as of Dec. 31—most of that stock tied up in orforglipron. That’s a sharp jump from the nearly $550 million reported last year. The company is pushing for an expedited U.S. review using an FDA Commissioner’s National Priority Voucher, a tool meant to speed up the process, but the target decision date now stands at April 10, according to the filing. Fierce Pharma
Pre-launch inventory—drug supplies produced before approval—lets companies move fast once they get the green light. But there’s a catch: if the FDA holds things up, requests tweaks, or if demand disappoints, firms are left holding expensive inventory.
“We’ve seen some comparable inventory builds before a launch, but this one’s a real outlier—much earlier and way bigger than you’d typically expect,” said Kevin Gade, chief operating officer at Bahl & Gaynor, a Lilly shareholder. For Gade, the strategy looks like Lilly wants to hit the ground running if approval comes through and grab as much market share as possible, fast. PharmExec
Traders now have their eyes on whether the inventory build addresses a key concern dogging obesity drug rollouts—can supply actually keep up with demand, or will bottlenecks and shadow markets emerge? The move also puts fresh focus on Lilly’s playbook for orforglipron compared to its injectables, like Mounjaro and Zepbound.
Still, an accelerated FDA review doesn’t guarantee speed to market. If the agency’s schedule slips, or if the label ends up tighter than bulls are betting, or payers balk at pricing, sentiment could sour fast—particularly since the stock’s already priced for perfection.
Once the FDA target date on April 10 passes, focus will shift to earnings. Lilly’s next report lands April 30, with investors watching closely for details on launch prep, capacity, and any early demand signals.
